[go: up one dir, main page]

US2232641A - Therapeutic composition and process of making it - Google Patents

Therapeutic composition and process of making it Download PDF

Info

Publication number
US2232641A
US2232641A US231236A US23123638A US2232641A US 2232641 A US2232641 A US 2232641A US 231236 A US231236 A US 231236A US 23123638 A US23123638 A US 23123638A US 2232641 A US2232641 A US 2232641A
Authority
US
United States
Prior art keywords
insulin
histone
metal
zinc
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US231236A
Inventor
Scott David Alymer
Fisher Albert Madden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
University of Toronto
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Priority to US231236A priority Critical patent/US2232641A/en
Application granted granted Critical
Publication of US2232641A publication Critical patent/US2232641A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins

Definitions

  • the blood-sugarlowering action of Insulin may be prolonged by using with the Insulin such substances as pro- 10 tamine, histone, and (in some animals) spermine.
  • the substances named form with the Insulin insoluble precipitates which, as experience shows, often adhere to the inside-of containers in which the compositions are stored. Further, these precipitates commonly form undesirably large aggregates which can not readily be adequately disintegrated. This tendency of the Insulin compositions to adhere to the walls of the containers and to form aggregates interferes with satisfactory use of the preparations; since, as is obvious, the precipitate, should remain completely and homogeneously suspended during withdrawal oi doses of the compositions.
  • Insulin-histone compositions embodying our present invention we ensure the 7 presence in those compositions 01 an amount of v unit of Insulin in crystals of Insulin.
  • Insulin crystallized with zinc contains about 0.52% ct zinc
  • Insulin crystallized with cadmium contains about 0.77% of cadmium
  • Insulin crystallized with nickel contains about 0.41% of nickel
  • 6 and Insulin crystallized with cobalt contains about 0.44% of cobalt, in terms of dry weight of the crystals; and one milligram of a dry preparation of Insulin, whether in crystalline form or in substantially pure amorphous form, contains 10 between 20 and 25 international units, the units used on this Continent.
  • Beneficial results are obtainable by having present in the Insulinhlst'one compositions as little as half a milligram of zinc (or molecularly equivalent amounts it 15 the other metals are used) per thousand units of the Insulin; and desirably, in order to ensure that not less than this quantity of metal be present,
  • Illustrations of our invention are as follows: 1. In any desired Way we makes. preparation of Insulin and histone, such as thymus histone,--as by adding the histoneto a solution of Insulin, commonly in the range of about 4 to mg. of histone per 1000 units of the Insulin.
  • the histone employed may be prepared by any 35 suitable process, such, for example, as that described by Nelson (Arch. f. exper. Path. u. Pharour second. Instead of only one of these four metals, we may add two or more. Preferably we add metal of the defined class in the form of chlorides, but we may add metal in elemental form, or in other forms, such as acetates, oxides,
  • the hydrogen-ion concentration can be adjusted to control the character of the resultant product. If it is desired to administer the composition in the form of a suspension, a desirable reaction is on the alkaline side of the isoelectric point of Insulinsay a reaction between pH 6.9 and 7.4. If, on the other hand, it is desired that the composition be'in the form of a solution, the hydrogen-ion concentration should be kept on the acid side of the isoelectric point of Insulin-say at a reaction of about pH 4.0. If desired, a suitable buffer may be added to maintain the hydrogen-ion concentration at the determined reaction.
  • composition of matter comprising Insulin, histone, and added metal of the class consisting of zinc, cadmium, nickel, and cobalt.
  • a composition oi matter comprising Insulin, histone, and a quantity of metal of the class consisting of zinc, cadmium, nickel, and cobalt which per unit of Insulin is at least twice as large molecularly as the quantity of metal present per unit of Insulin in crystals of Insulin.
  • composition of matter comprising Insulin, histone, and added zinc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Description

Patented Feb. 18, 1941 PATENT OFFICE THERAPEUTIC COMPOSITION AND. PROCESS OF MAKING IT David Alymer Scott, Forest Hill, and Albert Madden Fisher, Toronto, Ontario, Canada, assign ors to The Governors of the University of Toronto, Toronto, Ontario, Canada No Drawing. Application September 22, 1938, Serial No. 231,236
7 Claims. (01. 167-45) This application is a continuation in part of our application Serial No. 135,106, filed April 5, 1937.
It is the object of our present invention to enhance the utility of Insulin-histone compositions.
It has been demonstrated that the blood-sugarlowering action of Insulin may be prolonged by using with the Insulin such substances as pro- 10 tamine, histone, and (in some animals) spermine. At certain hydrogen-ion concentrations, the substances named form with the Insulin insoluble precipitates which, as experience shows, often adhere to the inside-of containers in which the compositions are stored. Further, these precipitates commonly form undesirably large aggregates which can not readily be adequately disintegrated. This tendency of the Insulin compositions to adhere to the walls of the containers and to form aggregates interferes with satisfactory use of the preparations; since, as is obvious, the precipitate, should remain completely and homogeneously suspended during withdrawal oi doses of the compositions.
We have discovered that the disadvantageous features noted above can be avoided, and in consequence the utility of the Insulin compositions can be enhanced, by having present in the compositions an adequate amount of metal of the class consisting of zinc, cadmium, nickel, and cobalt. Also we have discovered that by the presence of this amount of metal of the class defined the period of utility of the Insulin compositions is greatly lengthened. Moreover, we find that by the presence of this amount of either zinc or (sometimes) cadmium in the Insulin compositions the prolonged blood-sugar-lowering action of the compositions is extended. We here I assert no theory as to the nature of the actions of the metal present, or as to whether or not there is any chemical combination between the metal and either or both of the Insulin and the other component or components.
' This present application is directed to the us of these metals in connection with Insulinhistone preparations; for the use of those metals in connection with Insulin-protamine compositions is the subject of our Patent No. 2,179,384, granted November '7, 1939.
In preparing Insulin-histone compositions embodying our present invention we ensure the 7 presence in those compositions 01 an amount of v unit of Insulin in crystals of Insulin. (Insulin crystallized with zinc contains about 0.52% ct zinc, Insulin crystallized with cadmium contains about 0.77% of cadmium, Insulin crystallized with nickel contains about 0.41% of nickel, 6 and Insulin crystallized with cobalt contains about 0.44% of cobalt, in terms of dry weight of the crystals; and one milligram of a dry preparation of Insulin, whether in crystalline form or in substantially pure amorphous form, contains 10 between 20 and 25 international units, the units used on this Continent.) Beneficial results are obtainable by having present in the Insulinhlst'one compositions as little as half a milligram of zinc (or molecularly equivalent amounts it 15 the other metals are used) per thousand units of the Insulin; and desirably, in order to ensure that not less than this quantity of metal be present, we add at least this quantity. We may add any larger quantity of metal provided. only that the quantity added be not so large as to induce untoward reactions, such as undue pain Irom injections. We have obtained satisfactory results from adding 20 mg. of zinc (and also from adding molecularly equivalent quantities of the other metals) per 1000 units of Insulin. Most dew sirably we ensure the presence of a total 0! about 2 mg. of zinc per 1000 units of the Insulin.
Illustrations of our invention are as follows: 1. In any desired Way we makes. preparation of Insulin and histone, such as thymus histone,--as by adding the histoneto a solution of Insulin, commonly in the range of about 4 to mg. of histone per 1000 units of the Insulin. The histone employed may be prepared by any 35 suitable process, such, for example, as that described by Nelson (Arch. f. exper. Path. u. Pharour second. Instead of only one of these four metals, we may add two or more. Preferably we add metal of the defined class in the form of chlorides, but we may add metal in elemental form, or in other forms, such as acetates, oxides,
or hydroxides. Further, it is possible to ensure 50 metal has the function of preventing adherence and of their mixtures are not of prime importance.
In making such compositions available for clinical use, however, the hydrogen-ion concentration can be adjusted to control the character of the resultant product. If it is desired to administer the composition in the form of a suspension, a desirable reaction is on the alkaline side of the isoelectric point of Insulinsay a reaction between pH 6.9 and 7.4. If, on the other hand, it is desired that the composition be'in the form of a solution, the hydrogen-ion concentration should be kept on the acid side of the isoelectric point of Insulin-say at a reaction of about pH 4.0. If desired, a suitable buffer may be added to maintain the hydrogen-ion concentration at the determined reaction.
We claim as our invention:
1. The process of producing an Insulin-histone composition, which consists in putting Insulin and histone together, and ensuring the presence therewith of an amount of metal of the clas consisting of zinc, cadmium, nickel, and cobalt sufliclent to correspond molecularly to at least half a milligram of zinc per thousand units of the Insulin.
2. The process of producing an Insulin-histone composition, which consists in adding to Insulin a histone, and also adding metal of the class consisting of zinc, cadmium, nickel, and cobalt.
3. The process of producing an Insulin'-histone composition which consists in adding to Insulin a histone and zinc.
4. A composition of matter comprising Insulin, histone, and added metal of the class consisting of zinc, cadmium, nickel, and cobalt.
5. A composition oi matter, comprising Insulin, histone, and a quantity of metal of the class consisting of zinc, cadmium, nickel, and cobalt which per unit of Insulin is at least twice as large molecularly as the quantity of metal present per unit of Insulin in crystals of Insulin.
6. A composition of matter, comprising Insulin, histone, and added zinc.
'l. The process of producing an Insulin'-histone composition, which-consists in adding a histone toInsulin', and also adding metal oi. the class consisting of zinc, cadmium, nickel, and cobalt in sufiicient amountto make the total quantity of such metal present per unit of Insulin at least twice as large molecularly as the quantity 01' metal present per unit 0! Insulin in crystals 01 Insulin.
DAVID ALYMER SCOTT. ALBERT MADDEN FISHER.
US231236A 1938-09-22 1938-09-22 Therapeutic composition and process of making it Expired - Lifetime US2232641A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US231236A US2232641A (en) 1938-09-22 1938-09-22 Therapeutic composition and process of making it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US231236A US2232641A (en) 1938-09-22 1938-09-22 Therapeutic composition and process of making it

Publications (1)

Publication Number Publication Date
US2232641A true US2232641A (en) 1941-02-18

Family

ID=22868333

Family Applications (1)

Application Number Title Priority Date Filing Date
US231236A Expired - Lifetime US2232641A (en) 1938-09-22 1938-09-22 Therapeutic composition and process of making it

Country Status (1)

Country Link
US (1) US2232641A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787575A (en) * 1950-11-22 1957-04-02 Organon Zinc-glycine-insulin composition and production thereof
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
DE971500C (en) * 1950-11-22 1959-02-05 Organon Nv Process for the production of insulin suspensions with prolonged action

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787575A (en) * 1950-11-22 1957-04-02 Organon Zinc-glycine-insulin composition and production thereof
DE971500C (en) * 1950-11-22 1959-02-05 Organon Nv Process for the production of insulin suspensions with prolonged action
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same

Similar Documents

Publication Publication Date Title
Turner Studies on the prevention of cholesterol atherosclerosis in rabbits: I. The effects of whole thyroid and of potassium iodide
White et al. Enhancing effects of growth hormone on renal function
JP4995780B2 (en) Low pH bactericidal iodine composition with increased stability
Ingle et al. A comparison of the effects of 11-desoxycorticosterone acetate and 17-hydroxy-11-dehydro-corticosterone in partially depancreatized rats
US2232641A (en) Therapeutic composition and process of making it
US3356570A (en) Composition for treating shock
Kochakian HISTOCHEMICAL STUDY OF ‘ALKALINE’PHOSPHATASE THE KIDNEY OF THE CASTRATED MOUSE AFTER STIMULATION WITH VARIOUS ANDROGENS
US2179384A (en) Therapeutic composition and process of making it
Marks et al. Reactivity to aversive stimuli as a function of alterations in body weight in normal and gonadectomized female rats
US2876159A (en) Dithiocarbamates for treatment of nickel poisoning
Smith Effects of fluorine upon rate of eruption of rat incisors, and its correlation with bone development and body growth
Dowben et al. Effects of steroids on the course of hereditary muscular dystrophy in mice
US1429276A (en) Tablet for producing iodine
US2004891A (en) Anaesthetic composition
Van Liere et al. Regression of cardiac hypertrophy following experimental hyperthyroidism in rats
Irving et al. The Effect of Sodium Fluoride on the Teeth and Blood Calcium and Inorganic Phosphorus Levels of Rachitic Rats'
CA1042797A (en) Aqueous rafoxanide formulations
Remy et al. Liver xanthine oxidase and Qo2 in relation to thyroid activity
US2547144A (en) Anticoccidiotic composition
US2352012A (en) Sulphanilamide addition compound
HOGNESS et al. Effects of Amphenone “B” on thyroid and adrenal functions
Loeser et al. A study of the toxicity of strontium and comparison with other cations employed in therapeutics
Shapiro A preliminary report on the use of cesium chloride in contrast radiography
Shelton et al. Experimental use of testosterone compounds in premature infants
Bargeron et al. The importance of an adequate circulating blood volume following superior vena cava—right pulmonary artery anastomosis